High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking

John Jr Crabbe, Angela Ozburn, Pamela Metten, Amanda Barkley-Levenson, Jason P. Schlumbohm, Stephanie E. Spence, Wyatt R. Hack, Lawrence C. Huang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background There is a serious public health need for better understanding of alcohol use disorder disease mechanisms and for improved treatments. At this writing, only three drugs are approved by the Food and Drug Administration as medications to treat alcohol use disorders – disulfiram, naltrexone, and acamprosate. Binge drinking is a form of abusive alcohol drinking defined by the NIAAA as a drinking to blood alcohol levels (BALs) > 0.08% during a period of approximately 2 h. To model genetic risk for binge-like drinking, we have used selective breeding to create a unique animal model, High Drinking in the Dark (HDID) mice. Behavioral characterization of HDID mice has revealed that HDID mice exhibit behavioral impairment after drinking, withdrawal after a single binge-drinking session, and escalate their intake in response to induction of successive cycles of dependence. Notably, HDID mice do not exhibit altered tastant preference or alcohol clearance rates. We therefore asked whether drugs of known clinical relevance could modulate binge-like ethanol drinking in HDID mice, reasoning that this characterization of HDID responses should inform future use of this genetic animal model for screening and development of novel potential therapeutics. Methods We tested the efficacy of acamprosate and naltrexone to reduce binge-like drinking in HDID mice. Additionally, we tested the GABAB receptor agonist, baclofen, based on recent pre-clinical and clinical studies demonstrating that it reduces alcohol drinking. We elected not to include disulfiram due to its more limited clinical usage. Mice were tested after acute doses of drugs in the limited-access Drinking in the Dark (DID) paradigm. Results HDID mice were sensitive to the effects of acamprosate and baclofen, but not naltrexone. Both drugs reduced binge-like drinking. However, naltrexone failed to reduce drinking in HDID mice. Thus, HDID mice may represent a useful model for screening novel compounds.

Original languageEnglish (US)
Pages (from-to)55-62
Number of pages8
JournalPharmacology Biochemistry and Behavior
Volume160
DOIs
StatePublished - Sep 1 2017

Fingerprint

Binge Drinking
Drinking
Naltrexone
Alcohols
Pharmaceutical Preparations
Disulfiram
Baclofen
Screening
Animals
Public health
Genetic Models
Blood
Ethanol
Alcohol Drinking
National Institute on Alcohol Abuse and Alcoholism (U.S.)
Animal Models
GABA-B Receptors
acamprosate
United States Food and Drug Administration

Keywords

  • Binge
  • Drinking in the dark
  • Genetic animal model
  • Mouse
  • Pharmacotherapy

ASJC Scopus subject areas

  • Biochemistry
  • Toxicology
  • Pharmacology
  • Clinical Biochemistry
  • Biological Psychiatry
  • Behavioral Neuroscience

Cite this

High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking. / Crabbe, John Jr; Ozburn, Angela; Metten, Pamela; Barkley-Levenson, Amanda; Schlumbohm, Jason P.; Spence, Stephanie E.; Hack, Wyatt R.; Huang, Lawrence C.

In: Pharmacology Biochemistry and Behavior, Vol. 160, 01.09.2017, p. 55-62.

Research output: Contribution to journalArticle

Crabbe, John Jr ; Ozburn, Angela ; Metten, Pamela ; Barkley-Levenson, Amanda ; Schlumbohm, Jason P. ; Spence, Stephanie E. ; Hack, Wyatt R. ; Huang, Lawrence C. / High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking. In: Pharmacology Biochemistry and Behavior. 2017 ; Vol. 160. pp. 55-62.
@article{e6c3e39c5e8145528358da60c82abaac,
title = "High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking",
abstract = "Background There is a serious public health need for better understanding of alcohol use disorder disease mechanisms and for improved treatments. At this writing, only three drugs are approved by the Food and Drug Administration as medications to treat alcohol use disorders – disulfiram, naltrexone, and acamprosate. Binge drinking is a form of abusive alcohol drinking defined by the NIAAA as a drinking to blood alcohol levels (BALs) > 0.08{\%} during a period of approximately 2 h. To model genetic risk for binge-like drinking, we have used selective breeding to create a unique animal model, High Drinking in the Dark (HDID) mice. Behavioral characterization of HDID mice has revealed that HDID mice exhibit behavioral impairment after drinking, withdrawal after a single binge-drinking session, and escalate their intake in response to induction of successive cycles of dependence. Notably, HDID mice do not exhibit altered tastant preference or alcohol clearance rates. We therefore asked whether drugs of known clinical relevance could modulate binge-like ethanol drinking in HDID mice, reasoning that this characterization of HDID responses should inform future use of this genetic animal model for screening and development of novel potential therapeutics. Methods We tested the efficacy of acamprosate and naltrexone to reduce binge-like drinking in HDID mice. Additionally, we tested the GABAB receptor agonist, baclofen, based on recent pre-clinical and clinical studies demonstrating that it reduces alcohol drinking. We elected not to include disulfiram due to its more limited clinical usage. Mice were tested after acute doses of drugs in the limited-access Drinking in the Dark (DID) paradigm. Results HDID mice were sensitive to the effects of acamprosate and baclofen, but not naltrexone. Both drugs reduced binge-like drinking. However, naltrexone failed to reduce drinking in HDID mice. Thus, HDID mice may represent a useful model for screening novel compounds.",
keywords = "Binge, Drinking in the dark, Genetic animal model, Mouse, Pharmacotherapy",
author = "Crabbe, {John Jr} and Angela Ozburn and Pamela Metten and Amanda Barkley-Levenson and Schlumbohm, {Jason P.} and Spence, {Stephanie E.} and Hack, {Wyatt R.} and Huang, {Lawrence C.}",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.pbb.2017.08.002",
language = "English (US)",
volume = "160",
pages = "55--62",
journal = "Pharmacology Biochemistry and Behavior",
issn = "0091-3057",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking

AU - Crabbe, John Jr

AU - Ozburn, Angela

AU - Metten, Pamela

AU - Barkley-Levenson, Amanda

AU - Schlumbohm, Jason P.

AU - Spence, Stephanie E.

AU - Hack, Wyatt R.

AU - Huang, Lawrence C.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background There is a serious public health need for better understanding of alcohol use disorder disease mechanisms and for improved treatments. At this writing, only three drugs are approved by the Food and Drug Administration as medications to treat alcohol use disorders – disulfiram, naltrexone, and acamprosate. Binge drinking is a form of abusive alcohol drinking defined by the NIAAA as a drinking to blood alcohol levels (BALs) > 0.08% during a period of approximately 2 h. To model genetic risk for binge-like drinking, we have used selective breeding to create a unique animal model, High Drinking in the Dark (HDID) mice. Behavioral characterization of HDID mice has revealed that HDID mice exhibit behavioral impairment after drinking, withdrawal after a single binge-drinking session, and escalate their intake in response to induction of successive cycles of dependence. Notably, HDID mice do not exhibit altered tastant preference or alcohol clearance rates. We therefore asked whether drugs of known clinical relevance could modulate binge-like ethanol drinking in HDID mice, reasoning that this characterization of HDID responses should inform future use of this genetic animal model for screening and development of novel potential therapeutics. Methods We tested the efficacy of acamprosate and naltrexone to reduce binge-like drinking in HDID mice. Additionally, we tested the GABAB receptor agonist, baclofen, based on recent pre-clinical and clinical studies demonstrating that it reduces alcohol drinking. We elected not to include disulfiram due to its more limited clinical usage. Mice were tested after acute doses of drugs in the limited-access Drinking in the Dark (DID) paradigm. Results HDID mice were sensitive to the effects of acamprosate and baclofen, but not naltrexone. Both drugs reduced binge-like drinking. However, naltrexone failed to reduce drinking in HDID mice. Thus, HDID mice may represent a useful model for screening novel compounds.

AB - Background There is a serious public health need for better understanding of alcohol use disorder disease mechanisms and for improved treatments. At this writing, only three drugs are approved by the Food and Drug Administration as medications to treat alcohol use disorders – disulfiram, naltrexone, and acamprosate. Binge drinking is a form of abusive alcohol drinking defined by the NIAAA as a drinking to blood alcohol levels (BALs) > 0.08% during a period of approximately 2 h. To model genetic risk for binge-like drinking, we have used selective breeding to create a unique animal model, High Drinking in the Dark (HDID) mice. Behavioral characterization of HDID mice has revealed that HDID mice exhibit behavioral impairment after drinking, withdrawal after a single binge-drinking session, and escalate their intake in response to induction of successive cycles of dependence. Notably, HDID mice do not exhibit altered tastant preference or alcohol clearance rates. We therefore asked whether drugs of known clinical relevance could modulate binge-like ethanol drinking in HDID mice, reasoning that this characterization of HDID responses should inform future use of this genetic animal model for screening and development of novel potential therapeutics. Methods We tested the efficacy of acamprosate and naltrexone to reduce binge-like drinking in HDID mice. Additionally, we tested the GABAB receptor agonist, baclofen, based on recent pre-clinical and clinical studies demonstrating that it reduces alcohol drinking. We elected not to include disulfiram due to its more limited clinical usage. Mice were tested after acute doses of drugs in the limited-access Drinking in the Dark (DID) paradigm. Results HDID mice were sensitive to the effects of acamprosate and baclofen, but not naltrexone. Both drugs reduced binge-like drinking. However, naltrexone failed to reduce drinking in HDID mice. Thus, HDID mice may represent a useful model for screening novel compounds.

KW - Binge

KW - Drinking in the dark

KW - Genetic animal model

KW - Mouse

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=85027532418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027532418&partnerID=8YFLogxK

U2 - 10.1016/j.pbb.2017.08.002

DO - 10.1016/j.pbb.2017.08.002

M3 - Article

VL - 160

SP - 55

EP - 62

JO - Pharmacology Biochemistry and Behavior

JF - Pharmacology Biochemistry and Behavior

SN - 0091-3057

ER -